49
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antimicrobial Compounds from Eukaryotic Microalgae against Human Pathogens and Diseases in Aquaculture

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The search for novel compounds of marine origin has increased in the last decades for their application in various areas such as pharmaceutical, human or animal nutrition, cosmetics or bioenergy. In this context of blue technology development, microalgae are of particular interest due to their immense biodiversity and their relatively simple growth needs. In this review, we discuss about the promising use of microalgae and microalgal compounds as sources of natural antibiotics against human pathogens but also about their potential to limit microbial infections in aquaculture. An alternative to conventional antibiotics is needed as the microbial resistance to these drugs is increasing in humans and animals. Furthermore, using natural antibiotics for livestock could meet the consumer demand to avoid chemicals in food, would support a sustainable aquaculture and present the advantage of being environmentally friendly. Using natural and renewable microalgal compounds is still in its early days, but considering the important research development and rapid improvement in culture, extraction and purification processes, the valorization of microalgae will surely extend in the future.

          Related collections

          Most cited references206

          • Record: found
          • Abstract: found
          • Article: not found

          Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

          The increased use of antibacterial and antifungal agents in recent years has resulted in the development of resistance to these drugs. The significant clinical implication of resistance has led to heightened interest in the study of antimicrobial resistance from different angles. Areas addressed include mechanisms underlying this resistance, improved methods to detect resistance when it occurs, alternate options for the treatment of infections caused by resistant organisms, and strategies to prevent and control the emergence and spread of resistance. In this review, the mode of action of antifungals and their mechanisms of resistance are discussed. Additionally, an attempt is made to discuss the correlation between fungal and bacterial resistance. Antifungals can be grouped into three classes based on their site of action: azoles, which inhibit the synthesis of ergosterol (the main fungal sterol); polyenes, which interact with fungal membrane sterols physicochemically; and 5-fluorocytosine, which inhibits macromolecular synthesis. Many different types of mechanisms contribute to the development of resistance to antifungals. These mechanisms include alteration in drug target, alteration in sterol biosynthesis, reduction in the intercellular concentration of target enzyme, and overexpression of the antifungal drug target. Although the comparison between the mechanisms of resistance to antifungals and antibacterials is necessarily limited by several factors defined in the review, a correlation between the two exists. For example, modification of enzymes which serve as targets for antimicrobial action and the involvement of membrane pumps in the extrusion of drugs are well characterized in both the eukaryotic and prokaryotic cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Commercial potential for Haematococcus microalgae as a natural source of astaxanthin.

            As a result of high production costs, commercial products from microalgae must command high prices. Astaxanthin produced by Haematococcus is a product that has become a commercial reality through novel and advanced technology. Cultivation methods have been developed to produce Haematococcus containing 1.5-3.0% astaxanthin by dry weight, with potential applications as a pigment source in aquaculture, poultry feeds and in the worldwide nutraceutical market.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vibrio harveyi: a significant pathogen of marine vertebrates and invertebrates.

              Vibrio harveyi, which now includes Vibrio carchariae as a junior synonym, is a serious pathogen of marine fish and invertebrates, particularly penaeid shrimp. In fish, the diseases include vasculitis, gastro-enteritis and eye lesions. With shrimp, the pathogen is associated with luminous vibriosis and Bolitas negricans. Yet, the pathogenicity mechanisms are imprecisely understood, with likely mechanisms involving the ability to attach and form biofilms, quorum sensing, various extracellular products including proteases and haemolysins, lipopolysaccharide, and interaction with bacteriophage and bacteriocin-like substances.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Mar Drugs
                Mar Drugs
                marinedrugs
                Marine Drugs
                MDPI
                1660-3397
                02 September 2016
                September 2016
                : 14
                : 9
                : 159
                Affiliations
                [1 ]FR CNRS 3473 IUML Mer-Molécules-Santé (MMS), Université du Maine, Avenue O. Messiaen, Le Mans 72085, France; Charlotte.Falaise@ 123456gmail.com (C.F.); gastineauromain@ 123456yahoo.fr (R.G.); Yann.Hardivillier@ 123456univ-lemans.fr (Y.H.); Vincent.Leignel@ 123456univ-lemans.fr (V.L.)
                [2 ]Ifremer, SG2M-LGPMM, Laboratoire de Génétique et de Pathologie des Mollusques Marins, Avenue Mus de Loup, La Tremblade 17390, France; Cyrille.Francois@ 123456ifremer.fr (C.F.); Marie.Agnes.Travers@ 123456ifremer.fr (M.-A.T.); Benjamin.Morga@ 123456ifremer.fr (B.M.); Joel.Haure@ 123456ifremer.fr (J.H.)
                [3 ]Institut des Sciences de la Mer de Rimouski, Université du Québec à Rimouski, 310 des Ursulines, Rimouski, QC G5L 3A1, Canada; Rejean_Tremblay@ 123456uqar.ca (R.T.); Francois.Turcotte@ 123456uqar.ca (F.T.)
                [4 ]UMR CNRS 6283 Institut des Molécules et Matériaux du Mans (IMMM), Université du Maine, Avenue O. Messiaen, Le Mans 72085, France; Pamela.Pasetto@ 123456univ-lemans.fr
                Author notes
                [* ]Correspondence: Jean-Luc.Mouget@ 123456univ-lemans.fr ; Tel.: +33-243-833-242
                Article
                marinedrugs-14-00159
                10.3390/md14090159
                5039530
                27598176
                c2eaa59d-dd20-4bbe-b35c-f8b54b1a916f
                © 2016 by the authors; licensee MDPI, Basel, Switzerland.

                This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 12 July 2016
                : 24 August 2016
                Categories
                Review

                Pharmacology & Pharmaceutical medicine
                biological activity,antimicrobial,antibacterial,antifungal,antiviral,haslea,microalgae,sustainable aquaculture

                Comments

                Comment on this article